Ausgabe 2/2010
Inhalt (24 Artikel)
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients
Chee M. Ng, S. Bai, C. H. Takimoto, M. T. Tang, A. W. Tolcher
Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer
Junichi Kurebayashi, Mamoru Nukatsuka, Hiroshi Sonoo, Junji Uchida, Mamoru Kiniwa
A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer
Francisco Robert, Karen Harper, Judie Ackerman, Sunil Gupta
Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors
Apostolia Maria Tsimberidou, Michelle A. Rudek, David Hong, Chaan S. Ng, Jessica Blair, Howard Goldsweig, Razelle Kurzrock
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors
Toshio Shimizu, Isamu Okamoto, Kenji Tamura, Taroh Satoh, Masaki Miyazaki, Yusaku Akashi, Tomohiro Ozaki, Masahiro Fukuoka, Kazuhiko Nakagawa
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer
Ken-ichi Fujita, Yuichi Ando, Wataru Yamamoto, Toshimichi Miya, Hisashi Endo, Yu Sunakawa, Kazuhiro Araki, Keiji Kodama, Fumio Nagashima, Wataru Ichikawa, Masaru Narabayashi, Yuko Akiyama, Kaori Kawara, Mari Shiomi, Hiroyasu Ogata, Hiroyasu Iwasa, Yasushi Okazaki, Takashi Hirose, Yasutsuna Sasaki
Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study
Muh-Hwa Yang, Peter Mu-Hsin Chang, Cheng-Hwai Tzeng, Shyue-Yih Chang, Pen-Yuan Chu, Shyh-Kuan Tai, Tung-Lung Tsai, Yi-Feng Wang, Jui-Lin Huang, Hung-Ming Wang, Po-Min Chen
Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism
Amanda Leite Bastos-Pereira, Daiana Lugarini, Adriana de Oliveira-Christoff, Thiago Vinicius Ávila, Simone Teixeira, Amanda do Rocio Andrade Pires, Marcelo Nicolás Muscará, Sílvia Maria Suter Correia Cadena, Lucélia Donatti, Helena Cristina da Silva de Assis, Alexandra Acco
Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells
Gangjun Du, Haihong Lin, Mei Wang, Shuo Zhang, Xianchuang Wu, Linlin Lu, Liyan Ji, Lijuan Yu
Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines
Seema-Maria Nathwani, Stephen Butler, Mary J. Meegan, Giuseppe Campiani, Mark Lawler, D. Clive Williams, Daniela M. Zisterer
Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call®) in patients with unresectable hepatocellular carcinoma
Yo-ichi Yamashita, Akinobu Taketomi, Shinji Itoh, Norifumi Harimoto, Kazutoyo Morita, Takasuke Fukuhara, Shigeru Ueda, Kensaku Sanefuji, Keishi Sugimachi, Tsuyoshi Tajima, Yoshihiko Maehara
Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat
Tanushree Das, Falguni Patra, Biswajit Mukherjee
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials
Nse Ntukidem, Carlos Arce-Lara, Gregory A. Otterson, Eric Kraut, Spero Cataland, Tanios Bekaii-Saab
Quantitative structure–property relationships of camptothecins in humans
Chao Xu, Thomas M. Barchet, Donald E. Mager
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences
Amalia Azzariti, Letizia Porcelli, Grazia M. Simone, Anna E. Quatrale, Nicola A. Colabufo, Francesco Berardi, Roberto Perrone, Massimo Zucchetti, Maurizio D’Incalci, Jian Ming Xu, Angelo Paradiso
The effect of transcatheter arterial chemoembolization on phase II drug metabolism enzymes in patients with hepatocellular carcinoma
Yan Zhang, Yanyan Jia, Xinyou Liu, Linna Liu, Qingwei Wang, Aidong Wen
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
Brian Thiessen, Clinton Stewart, Ming Tsao, Suzanne Kamel-Reid, Paula Schaiquevich, Warren Mason, Jacob Easaw, Karl Belanger, Peter Forsyth, Lynn McIntosh, Elizabeth Eisenhauer
A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts
Mika Endo, Masanori Miwa, Masako Ura, Hiromi Tanimura, Kenji Taniguchi, Yoko Miyazaki, Jun Ohwada, Masao Tsukazaki, Satoshi Niizuma, Takeshi Murata, Sawako Ozawa, Hitomi Suda, Kotaro Ogawa, Eitaro Nanba, Shunsuke Nagao, Nobuo Shimma, Hisafumi Yamada-Okabe
A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma
Hyun Young Woo, Si Hyun Bae, Jun Yong Park, Kwang Hyub Han, Ho Jong Chun, Byung Gil Choi, Hyeon U. Im, Jong Young Choi, Seung Kew Yoon, Jae Youn Cheong, Sung Won Cho, Byoung Kuk Jang, Jae Seok Hwang, Sang Gyune Kim, Young Seok Kim, Yeon Seok Seo, Hyung Joon Yim, Soon Ho Um
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
Shivaani Kummar, Martin E. Gutierrez, Erin R. Gardner, William D. Figg, Giovanni Melillo, Janet Dancey, Edward A. Sausville, Barbara A. Conley, Anthony J. Murgo, James H. Doroshow
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme
Giulio Metro, Alessandra Fabi, Maria A. Mirri, Antonello Vidiri, Andrea Pace, Mariantonia Carosi, Michelangelo Russillo, Marta Maschio, Diana Giannarelli, Domenica Pellegrini, Alfredo Pompili, Francesco Cognetti, Carmine M. Carapella
Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report
Ticiana Leal, H. Ian Robins
The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients
Aathavan Loganayagam, Monica Arenas-Hernandez, Lynette Fairbanks, Paul Ross, Jeremy D. Sanderson, Anthony M. Marinaki